Land: USA
Språk: engelsk
Kilde: NLM (National Library of Medicine)
MANNITOL (UNII: 3OWL53L36A) (MANNITOL - UNII:3OWL53L36A)
Hospira, Inc.
MANNITOL
MANNITOL 5 g in 100 mL
INTRAVENOUS
PRESCRIPTION DRUG
Mannitol Injection is indicated for the reduction of: - intracranial pressure and treatment of cerebral edema. - elevated intraocular pressure. Mannitol Injection is contraindicated in patients with: - Known hypersensitivity to mannitol [see Warnings and Precautions (5.1)]. - Anuria [see Warnings and Precautions (5.2)]. - Severe hypovolemia [see Warnings and Precautions (5.4)]. - Pre-existing severe pulmonary vascular congestion or pulmonary edema [see Warnings and Precautions (5.5)] . - Active intracranial bleeding except during craniotomy. Risk Summary The available case report data with mannitol over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Mannitol crosses the placenta and may cause fluid shifts that could potentially result in adverse effects in the fetus (see Data) .No adverse developmental effects from mannitol were reported in published animal studies; however, fluid shifts occurred in fetal ewes in resp
Mannitol Injection 25%, USP is available as 12.5 g/50 mL (0.25 g/mL) of mannitol in a single-dose vial. Supplied as a tray of 25 vials (NDC 0409-4031-01). Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Protect from freezing.
New Drug Application
MANNITOL- MANNITOL INJECTION, SOLUTION HOSPIRA, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE MANNITOL INJECTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR MANNITOL INJECTION. MANNITOL INJECTION, FOR INTRAVENOUS USE INITIAL U.S. APPROVAL: 1964 RECENT MAJOR CHANGES Indications and Usage (removed, revised) (1) 03/2020 Contraindications (4) 03/2020 Warnings and Precautions (5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7) 03/2020 INDICATIONS AND USAGE Mannitol Injection is an osmotic diuretic, indicated for the reduction of: intracranial pressure and treatment of cerebral edema. (1) elevated intraocular pressure. (1) DOSAGE AND ADMINISTRATION Administration Instructions (2.1): For intravenous infusion, preferably through a central venous catheter. Prior to administration, evaluate renal, cardiac and pulmonary status and correct fluid and electrolyte imbalances. Recommended Dosage (2.2): The dosage, concentration and rate of administration depend on the age, weight and condition of the patient, including fluid requirement, urinary output and concomitant therapy. _Reduction of Intracranial Pressure and Treatment of Cerebral Edema_: 0.25 g/kg administered every 6 to 8 hours as an intravenous infusion over at least 30 minutes. _Reduction of Intraocular Pressure: _1.5 to 2 g/kg administered as a single dose intravenously over at least 30 minutes. Administer 60 to 90 minutes before surgery to achieve maximal effect. DOSAGE FORMS AND STRENGTHS Mannitol Injection 25%, USP: 12.5 g/50 mL (0.25 g/mL) in a single-dose vial (3) CONTRAINDICATIONS Known hypersensitivity to mannitol. (4, 5.1) Anuria. (4, 5.2) Severe hypovolemia. (4, 5.4) Pre-existing severe pulmonary vascular congestion or pulmonary edema. (4, 5.5) Active intracranial bleeding except during craniotomy. (4) WARNINGS AND PRECAUTIONS Hypersensitivity Reactions, Including Anaphylaxis: Stop infusion immediately if hypersensitivity reactions develop. (5.1) Renal Complications Including Renal Fa read_full_document